Welcome to our dedicated page for Galecto SEC filings (Ticker: GLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Galecto, Inc. (NASDAQ: GLTO) SEC filings page on Stock Titan centralizes the company’s regulatory disclosures, giving investors structured access to official information about this clinical-stage biopharmaceutical issuer. Galecto files current and periodic reports with the U.S. Securities and Exchange Commission that describe its oncology and liver disease pipeline, capital structure and key corporate events.
For GLTO, Form 8-K filings are particularly important. Recent 8-Ks detail the acquisition of Damora Therapeutics and the resulting expansion into mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms, the related private placement of Series C non-voting convertible preferred stock, and the issuance of warrants under an antibody discovery and option agreement. Other 8-Ks describe executive appointments, inducement equity awards, and stockholder meeting results, providing insight into governance and leadership changes as Galecto advances DMR-001, DMR-002 and GB3226.
Annual and quarterly reports (Forms 10-K and 10-Q, when available) give more detailed views of Galecto’s research and development spending, general and administrative expenses, net losses and cash runway. These filings also summarize the status of key programs such as GB3226, a dual ENL-YEATS and FLT3 inhibitor for AML, and GB1211, a galectin-3 inhibitor for liver cirrhosis and oncology combinations. Investors can review risk factor discussions and management’s commentary on the company’s strategic focus on cancer and liver diseases.
On this page, Stock Titan pairs Galecto’s raw SEC documents with AI-powered summaries that highlight the main points of lengthy filings, helping users quickly identify material items such as mergers, financings, warrant issuances and preferred stock conversions. Real-time updates from EDGAR ensure new GLTO filings appear promptly, while access to insider-related disclosures, when filed on Form 4 or within other reports, can help users monitor equity grants and ownership changes involving directors and officers.
Whether you are analyzing Galecto’s evolving hematology-oncology pipeline, reviewing the terms of its private placements, or tracking its Nasdaq listing-related disclosures, this GLTO filings page offers a focused view of the company’s regulatory record with tools to make complex documents easier to understand.
Damora Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on June 17, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 22, 2026, when 60,303,212 common shares were outstanding, may vote.
Stockholders will elect two Class III directors to terms ending at the 2029 meeting, cast an advisory “say‑on‑pay” vote on named executive officer compensation, choose the frequency of future say‑on‑pay votes, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy statement outlines board and committee structure, director independence, executive and director pay, severance and change‑in‑control protections, and ownership and governance practices. It also notes the November 2025 Damora asset acquisition and the March 2026 rebranding from Galecto to Damora Therapeutics.
Damora Therapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders as a virtual-only event on June 17, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on April 22, 2026, when 60,303,212 common shares were outstanding, may vote.
Stockholders will elect two Class III directors to terms ending at the 2029 meeting, cast an advisory “say‑on‑pay” vote on named executive officer compensation, choose the frequency of future say‑on‑pay votes, and ratify Ernst & Young LLP as independent auditor for 2026.
The proxy statement outlines board and committee structure, director independence, executive and director pay, severance and change‑in‑control protections, and ownership and governance practices. It also notes the November 2025 Damora asset acquisition and the March 2026 rebranding from Galecto to Damora Therapeutics.
Damora Therapeutics, Inc. ownership filing: Paramora Holding LLC reports beneficial ownership of 2,045,473 shares of Common Stock, representing 3.39% of the class. The filing cites 60,303,212 shares outstanding as of March 17, 2026 and is signed on April 23, 2026.
The filing is an amendment to a Schedule 13G, noting ownership and voting/dispositive powers (sole voting power 2,045,473, sole dispositive power 2,045,473), and states the position is 5% or less of the class.
Damora Therapeutics, Inc. ownership filing: Paramora Holding LLC reports beneficial ownership of 2,045,473 shares of Common Stock, representing 3.39% of the class. The filing cites 60,303,212 shares outstanding as of March 17, 2026 and is signed on April 23, 2026.
The filing is an amendment to a Schedule 13G, noting ownership and voting/dispositive powers (sole voting power 2,045,473, sole dispositive power 2,045,473), and states the position is 5% or less of the class.
Paragon Therapeutics, Inc. amended its Schedule 13G to report beneficial ownership of 2,045,473 shares of Damora Therapeutics common stock. The filing states this position represents 3.39% of the class, calculated using 60,303,212 shares outstanding as of March 17, 2026 reported in Damora's Annual Report on Form 10-K. Paragon lists sole voting and sole dispositive power over the shares and is organized in Delaware. The amendment is signed by Keri Lantz, Chief Financial Officer on April 23, 2026.
Paragon Therapeutics, Inc. amended its Schedule 13G to report beneficial ownership of 2,045,473 shares of Damora Therapeutics common stock. The filing states this position represents 3.39% of the class, calculated using 60,303,212 shares outstanding as of March 17, 2026 reported in Damora's Annual Report on Form 10-K. Paragon lists sole voting and sole dispositive power over the shares and is organized in Delaware. The amendment is signed by Keri Lantz, Chief Financial Officer on April 23, 2026.
Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.
EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.
Damora Therapeutics, Inc. changed its independent auditor. On April 17, 2026, the Audit Committee dismissed EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm and appointed Ernst & Young LLP (EY US) effective immediately.
EY Denmark’s reports on the Company’s financial statements for 2025 and 2024 contained no adverse or qualified opinions, although the 2024 report included an explanatory paragraph about the Company’s ability to continue as a going concern. The Company reports no disagreements or reportable events with EY Denmark and states that it did not consult EY US on accounting or auditing matters before the engagement.
Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.
Damora Therapeutics director and officer Jennifer Jarrett received new equity awards as compensation. On March 30, 2026, she was granted stock options to purchase 1,500,000 shares of common stock at an exercise price of $25.50 per share, expiring March 30, 2036. The options vest 25% on March 30, 2027 and then in equal monthly installments through March 30, 2030, subject to continued service. She also received 500,000 restricted stock units, each representing one share of common stock, vesting 25% on each anniversary of the grant date over four years, also conditioned on continued service. Following these awards, she directly holds 500,000 shares of common stock and 1,500,000 options.
Damora Therapeutics, Inc. filed an initial insider ownership report for Jennifer Jarrett, who is listed as both a director and an officer (title noted as “See Remarks”). This Form 3 does not report any stock purchases, sales, option exercises, or other transactions in Damora Therapeutics shares.
Damora Therapeutics, Inc. filed an initial insider ownership report for Jennifer Jarrett, who is listed as both a director and an officer (title noted as “See Remarks”). This Form 3 does not report any stock purchases, sales, option exercises, or other transactions in Damora Therapeutics shares.
Damora Therapeutics, Inc. director Turtle Cameron received a grant of stock options covering 37,313 shares of common stock. The options carry an exercise price of $23.05 per share and expire on March 23, 2036.
The award vests in equal monthly installments through March 23, 2029, as long as Cameron continues to provide service to the company. Following this grant, Cameron holds stock options for 37,313 underlying shares directly, reflecting a compensation-related equity award rather than an open-market share purchase or sale.
Damora Therapeutics, Inc. director Turtle Cameron received a grant of stock options covering 37,313 shares of common stock. The options carry an exercise price of $23.05 per share and expire on March 23, 2036.
The award vests in equal monthly installments through March 23, 2029, as long as Cameron continues to provide service to the company. Following this grant, Cameron holds stock options for 37,313 underlying shares directly, reflecting a compensation-related equity award rather than an open-market share purchase or sale.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics director Michael Landsittel received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share and expires on March 23, 2036. It vests in equal monthly installments through March 23, 2029, contingent on his continued service. Following this grant, he holds options for 37,313 shares directly.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics, Inc. reported that director Christopher W. Cain was granted a stock option covering 37,313 shares of common stock at an exercise price of $23.05 per share. The option expires on March 23, 2036 and vests in equal monthly installments through March 23, 2029, conditioned on his continued service.
According to the disclosure, Cain holds this option for one or more investment vehicles managed by Fairmount Funds Management LLC, is required to turn over any net cash or stock from the option to Fairmount, and therefore disclaims beneficial ownership of both the option and the underlying shares. Fairmount also disclaims beneficial ownership except to the extent of its pecuniary interest.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.
Damora Therapeutics director Bruno Julianne received a stock option grant covering 37,313 shares of common stock. The option has an exercise price of $23.05 per share, carries no upfront cost, and will vest in equal monthly installments through March 23, 2029, conditioned on continued service. Following this award, Julianne holds options for 37,313 underlying shares directly.